Six organizations ask HHS Secretary Azar to take title of 5 patents on Exondys 51, as remedy to failure by inventors to disclose NIH funding

FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading

Six University of Pennsylvania and Daniel J. Rader patents on Juxtapid (lomitapide) failed to discuss multiple NIH grants

Update: In a letter dated March 28, 2018, Robert Firestone wrote to the NIH on behalf of Penn, stating that the NIH grants were infrastructure grants that did not give the NIH rights in the inventions. 2018-03-28-Penn-Response-juxtapid-Rader On March 19,… Continue Reading

KEI testimony at March 8, 2018 USTR Special 301 hearing, focusing on US compulsory licensing of patents

On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading

Orphan Drug Timeline

(More on this topic here: https://www.keionline.org/orphan-drugs and here.) 1980 April 17, 1980. Congresswoman Elizabeth Holtzman introduces H.R.7089 (96th Congress) – “A bill to establish an office in the National Institutes of Health to assist in the development of drugs for… Continue Reading

18 members of the House of Representatives call for compulsory license on patents for HCV treatments

Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading

Chilean Cámara de Diputados Votes Overwhelmingly To Proceed With Compulsory Licenses for HCV Drugs

The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading